Individual IL-3 priming is crucial for consistent in vitro activation of donor basophils in patients with chronic urticaria
Individual IL-3 priming is crucial for consistent in vitro activation of donor basophils in patients with chronic urticaria
复制标题
DOI：
10.1016/j.jaci.2011.07.021
复制
发表时间：
2011-12-01
影响因子：
14.2
通讯作者：
Hausmann, Oliver V.
中科院分区：
文献类型：
--
作者：
Gentinetta, Thomas;Pecaric-Petkovic, Tatjana;Hausmann, Oliver V.
背景资料：体内自体血清皮肤试验（ASST）是诊断慢性自发性荨麻疹（CU）患者的金标准，用于检测抗Fc ε RI或IgE本身的自身抗体以及其他自身反应性血清组分。共孵育的患者血清与捐助者嗜碱性粒细胞和测量其脱粒在体外可能是一个安全的替代方案，但已显示不一致的results.Objective：优化嗜碱性粒细胞活化试验，以检测自身反应性血清成分在CU patients.Methods：患者血清诱导CD 63和CD 203 c在捐助者嗜碱性粒细胞（n = 15）的能力测定通过流式细胞术。20例CU患者血清15例寒冷性荨麻疹患者和27例健康对照受试者被纳入，以优化供体嗜碱性粒细胞和嗜碱性粒细胞系的测试条件（RBL 703/21），然后对来自临床常规的110名连续患者进行测试。我们证明，单独的IL-3启动正常化最初不一致的嗜碱性粒细胞的反应性，并导致可重复的和可比的测试结果，无论使用的嗜碱性粒细胞供体。CD 203 c作为活化标志物和嗜碱性粒细胞系的使用不太适合于此目的。结论：对每个嗜碱性粒细胞供体进行个体化IL-3激发的嗜碱性粒细胞活化试验是ASST的可重复和可靠的替代方法。无意外感染风险，抗组胺药对检测结果无影响，结果可量化，并有可能提供治疗监测。患者血清中的脱粒因子的确切性质仍然是一个悬而未决的问题。（《过敏临床免疫学杂志》2011;128：1227-34。）
Background: The in vivo autologous serum skin test (ASST) is the diagnostic gold standard to detect autoantibodies against Fc epsilon RI or IgE itself, as well as other autoreactive serum components, in patients with chronic spontaneous urticaria (CU). Coincubation of patient sera with donor basophils and measuring their degranulation in vitro could be a safe alternative but has shown inconsistent results.Objective: Optimization of the basophil activation test to detect autoreactive serum components in patients with CU.Methods: The ability of patient sera to induce CD63 and CD203c in donor basophils (n = 15) was measured by means of flow cytometry. Sera of 20 patients with CU (10 with positive ASST results), 15 patients with cold urticaria, and 27 healthy control subjects were included to optimize test conditions with donor basophils and a basophil cell line (RBL703/21) followed by testing of 110 consecutive patients from clinical routine.Results: We demonstrate that individual IL-3 priming normalized the initially inconsistent basophil reactivity and led to reproducible and comparable test results irrespective of the basophil donors used. CD203c as an activation marker and the use of a basophil cell line were less suitable for this purpose.Conclusion: The basophil activation test with individualized IL-3 priming for each basophil donor is a reproducible and reliable alternative to the ASST. There are several advantages over the ASST: no risk of accidental infection, no influence of antihistamines on the test result, quantifiable results, and a potential in providing treatment monitoring. The exact nature of the degranulating factor or factors in patient sera remains an open question. (J Allergy Clin Immunol 2011;128:1227-34.)